SK3 Group Announces First Sales of Industry Leadin
Post# of 36729
Posted On: 04/22/2014 10:52:28 PM
SK3 Group Announces First Sales of Industry Leading Medical Cannabis Product T-Hydrocan(TM) RMC 40
LOS ANGELES, CA--(Marketwired - Apr 22, 2014) - SK3 Group, Inc. (OTC Pink: SKTO) (PINKSHEETS: SKTO) is pleased to announce that the first bottles of its new medicinal cannabis product, T-Hydrocan™ RMC 40, will be available this Wednesday, April 23, 2014, from Pharmajanes.com, and soon thereafter from collectives which carry the YAK Edibles line of medical marijuana products. The "RMC" designation indicates "refined mixed cannabinoids."
T-Hydrocan™ RMC 40 tablets contain 40 mg. of fully activated (decarboxylated) THC, along with the attendant cannabinoids that are found in the cannabis/hemp source material. The cannabis oils have been thoroughly refined utilizing organic processing materials which have been approved for contact with food, yielding a translucent red or gold colored essential oil containing highly concentrated cannabinoids, terpenes, terpenoids, amino acids, and other refined elements of the essential oil of cannabis.
T-Hydrocan™ RMC 40 is packaged 8 tablets per bottle. The suggested retail price is $35.00 per bottle.
T-Hydrocan™ RMC 40 was developed by Berkeley Bio-Organic Research Laboratories, Inc. and is available through Pharmajanes.com and select dispensaries throughout California. The next product in the T-Hydrocan™ product line will be T-Hydrocan™ Whole Plant 25 tablets and capsules.
"We are pleased to get this product to market so quickly," said Artemus Mayor, President of SK3 Group. "Licensing fees from this product will go straight to the company's bottom line and will give patients a high dosage capsule at an affordable price."
FDA Disclaimer
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent disease. Use only as directed.
About SK3
SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations
SK3
investors@medicalgreens.com
LOS ANGELES, CA--(Marketwired - Apr 22, 2014) - SK3 Group, Inc. (OTC Pink: SKTO) (PINKSHEETS: SKTO) is pleased to announce that the first bottles of its new medicinal cannabis product, T-Hydrocan™ RMC 40, will be available this Wednesday, April 23, 2014, from Pharmajanes.com, and soon thereafter from collectives which carry the YAK Edibles line of medical marijuana products. The "RMC" designation indicates "refined mixed cannabinoids."
T-Hydrocan™ RMC 40 tablets contain 40 mg. of fully activated (decarboxylated) THC, along with the attendant cannabinoids that are found in the cannabis/hemp source material. The cannabis oils have been thoroughly refined utilizing organic processing materials which have been approved for contact with food, yielding a translucent red or gold colored essential oil containing highly concentrated cannabinoids, terpenes, terpenoids, amino acids, and other refined elements of the essential oil of cannabis.
T-Hydrocan™ RMC 40 is packaged 8 tablets per bottle. The suggested retail price is $35.00 per bottle.
T-Hydrocan™ RMC 40 was developed by Berkeley Bio-Organic Research Laboratories, Inc. and is available through Pharmajanes.com and select dispensaries throughout California. The next product in the T-Hydrocan™ product line will be T-Hydrocan™ Whole Plant 25 tablets and capsules.
"We are pleased to get this product to market so quickly," said Artemus Mayor, President of SK3 Group. "Licensing fees from this product will go straight to the company's bottom line and will give patients a high dosage capsule at an affordable price."
FDA Disclaimer
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent disease. Use only as directed.
About SK3
SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations
SK3
investors@medicalgreens.com
(0)
(0)